A report by Kuick Research has highlighted the growing market for bispecific antibody drug conjugates (BsADCs). The paper, titled "Global Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape and Market Opportunity Insight 2025,” details exemplar partnerships in the field which indicate the market’s ripeness.
The combination of the antibody drug conjugate format with bispecificity has the potential to spur the emergence of a new generation of antibodies with enhanced selectivity and anti-tumour efficacy.
Kuick said in a press release: “The evolving understanding of cancer biology and advancing knowledge of antibody engineering are allowing firms to optimize the design of BsADCs, which can overcome early challenges associated with solid tumor therapy, such as resistance to standard therapy and poor tumor penetration.”
Further analysis from Kuick indicates that the first bispecific antibody drug conjugate is anticipated to become available by 2029. Currently, there are more than 100 bispecific antibody drug conjugates undergoing clinical trials worldwide. These trials provide valuable insights across multiple dimensions, including companies, countries, indications, and phases.
China leads the global development landscape, with over 60 bispecific antibody drug conjugates in progress. The majority of these candidates are focused on cancer therapies, with more than 40 targeting this category. Additional information is also available regarding development platforms and the competitive landscape within the field.
One such example of a therapeutic candidate in this space is Avenzo Therapeutics’ and DualityBio’s AVZO-1418/DB-1418, which recently received IND approval, and was taken into the clinic in July 2025. The candidate was generated using DualityBio’s DISAC discovery platform who entered into an exclusive license agreement whereby Avenzo Therapeutics could develop, manufacture, and commercialise it.
This BsADC targets EGFR and HER3 in patients with advanced solid tumours. Both well-trodden are targets in bispecifics for cancers.
When the collaboration was announced, Athena Countouriotis, Co-founder, President, and CEO of Avenzo Therapeutics said: “By targeting both EGFR and HER3 with its differentiated design, AVZO-1418/DB-1418 has the potential to provide clinical benefit across multiple solid tumor types. We are excited to add this drug candidate to our clinical pipeline and look forward to collaborating with DualityBio to quickly progress this program into clinical studies.”
The report stressed: “These collaborations are essential in pushing the pipeline forward, combining strengths in antibody development, conjugation technology, and manufacturing to streamline the process from preclinical research to commercialisation.”
